Drug Trial Radar · NCT03838848
KN046 in Patients With Advanced Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Mar 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
120
Actual
Start
May 5, 2019
Primary completion
Jul 30, 2022
Study completion Jul 30, 2022
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, open label, multicenter study in subjects with advanced non-small cell lung cancer.
Conditions
- Stage IV Non-small Cell Lung Cancer
Interventions
KN046Drug
3mg/kg, Q2W, intravenous injection (IV)
KN046Drug
5mg/kg, Q2W, intravenous injection (IV)
KN046Drug
5mg/kg, Q3W, intravenous injection (IV)
CarboplatinDrug
AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.
PemetrexedDrug
500 mg/m2, Q3W, intravenous injection (IV)
NingetinibDrug
Oral, QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 2 years
- DORTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.